Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY24 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Nov 7, 2023
Slide 1: Cover letter to stock exchanges
07th November, 2023 To, The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Dear Sirs, Sub: Press
Slide 2: Press Release: Alkem reports Q2FY24 and H1FY24 results
Press Release Alkem reports Q2FY24 and H1FY24 results Mumbai, November 7, 2023: Alkem Laboratories Ltd. (Alkem) today announced its standalone and consolidated financial results for the second quarter ended September 30, 2023. These results were taken on record by the Board of Directors at its meeti
Slide 3: Operational Highlights: Domestic Business
Operational Highlights Domestic Business In Q2FY24, the Company’s India sales increased by 5.0% YoY, recording sales of ₹ 23,278 million as compared to ₹ 22,161 million in Q2FY23. For H1FY24, the Company’s India sales was ₹ 42,285 million compared to ₹ 39,976 million in H1FY23 – growth of 5.8% YoY.
Slide 4: International Business and R&D Investments
International Business In Q2FY24, the Company’s International sales grew by 27.1% YoY, recording sales of ₹ 10,542 million as compared to ₹ 8,291 million in Q2FY23. For H1FY24, the Company’s International sales grew by 30.2% to ₹ 20,688 million compared to ₹ 15,895 million in H1FY23. • US sales for
Slide 5: Q2FY24 and H1FY24 Conference Call details
Q2FY24 and H1FY24 Conference Call at 5:30 pm IST, November 7, 2023 Alkem will organize a conference call for investors and analysts on Tuesday, November 7, 2023 from 5:30pm to 6:30pm IST to discuss its Q2FY24 financial results. Alkem will be represented on the call by Mr. Vikas Gupta, Chief Executiv
Slide 6: Investor Presentation Q2FY24
Investor Presentation Q2FY24 November 7, 2023
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q2FY24
Key Highlights of Q2FY24 • Revenue from Operation grew by 11.7% YoY during the quarter, with EBITDA margin of 21.7% and Net Profit margin of 18.0% • India Business: As per IQVIA, Company’s sales in Q2FY24 registered growth of 6.5% compared to IPM growth of 7.0% • Domestic market displayed moderate g
Slide 9: Key Financial Highlights – Q2FY24 (Consolidated)
Key Financial Highlights – Q2FY24 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 22,161 23,278 34,402 30,794 Q2FY23 Q2FY24 International sales 10,542 8,291 Q2FY23 Q2FY24 Q2FY23 Q2FY24
Slide 10: Key Financial Highlights – Q2FY24 (Consolidated)
Key Financial Highlights – Q2FY24 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 7,467 21,131 17,724 4,539 57.6% 61.4% 14.7% 21.7% Q2FY23 Q2FY24 Q2FY23 Q2FY24 Q2FY24 was impacted PAT (after Minority Interest) PBT (after exceptional item) by exceptional item
Slide 11: Key Financial Highlights – H1FY24 (Consolidated)
Key Financial Highlights – H1FY24 (Consolidated) All figures in ₹ mn Particulars H1FY24 H1FY23 YoY growth Revenue from Operations 64,079 56,558 13.3% Gross Profit 38,823 32,534 19.3% Gross Profit Margin 60.6% 57.5% EBITDA 11,359 6,572 72.9% EBITDA Margin 17.7% 11.6% PBT (before exceptional item) 10,
Slide 12: India Business
India Business India Business: Q2FY24 Sales of ₹ 23,278 million (5.0% YoY growth) • Contribution of domestic sales to total sales in Q2 FY24 was 68.8% • As per IQVIA, in Q2FY24, the Company’s secondary sales grew by 6.5% compared to IPM growth of 7.0% YoY. • Although there has been subdued growth in
Slide 13: Secondary Sales Performance
Secondary Sales Performance Mixed performance across all major therapeutic segments in Q2FY24 1 3 3 2 Market rank Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 14.7% 8.4% 7.9% 7.3% 6.9% 6.0% 1.3% 1.7% Alkem sales growth YoY1,2 Indian pharma industr
Slide 14: US Business
US Business US Business: Q2FY24 Sales of ₹ 7,675 million (27.1% YoY growth) • Overall contribution of US sales to total sales was 22.7% in Q2FY24 • During the quarter, the US business registered strong growth of 27.1% YoY and 10.4% QoQ. • During Q2FY24, the Company received 4 ANDA approvals (includi
Slide 15: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Ankleshwar (India) API April 2023 Inspection is closed. EIR# received in July 2023 St. Louis (US) Formulations November 2022 Inspection is closed. EIR# received in December 2022 Bioequivalence Ta
Slide 16: Other International Business
Other International Business Other International Business: Q2FY24 Sales of ₹ 2,866 million (27.3% YoY growth) • Other International Market sales contributed 8.5% to total sales in Q2FY24 • The Company has presence mainly in Latin America, Australia, Europe, South East Asia, Africa and CIS. • All our
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2023 Non-Institution, 19.59% Promoter & Promoter Group, 56.74% Institution, 23.67% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 18: Thank You
Thank You For further information or queries, please contact Amit Kumar Khandelia VP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com